These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8383753)

  • 1. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin.
    Manning M; Sawyer WH
    J Recept Res; 1993; 13(1-4):195-214. PubMed ID: 8383753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxytocin pretreatment enhances arginine vasopressin-induced motor disturbances and arginine vasopressin-induced phosphoinositol hydrolysis in rat septum: a cross-sensitization phenomenon.
    Poulin P; Pittman QJ
    J Neuroendocrinol; 1993 Feb; 5(1):33-9. PubMed ID: 8387375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.
    Manning M; Misicka A; Olma A; Bankowski K; Stoev S; Chini B; Durroux T; Mouillac B; Corbani M; Guillon G
    J Neuroendocrinol; 2012 Apr; 24(4):609-28. PubMed ID: 22375852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors.
    Yibchok-anun S; Hsu WH
    Life Sci; 1998; 63(21):1871-8. PubMed ID: 9825765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
    Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
    J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors.
    Busnelli M; Bulgheroni E; Manning M; Kleinau G; Chini B
    J Pharmacol Exp Ther; 2013 Aug; 346(2):318-27. PubMed ID: 23723434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pharmacology of human vasopressin receptors.
    Thibonnier M; Conarty DM; Preston JA; Wilkins PL; Berti-Mattera LN; Mattera R
    Adv Exp Med Biol; 1998; 449():251-76. PubMed ID: 10026814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity of new neurohypophyseal hormones analogues conformationally restricted in the N-terminal part of the molecule. Highly potent OT receptor antagonists.
    Kwiatkowska A; Ptach M; Borovičková L; Slaninová J; Lammek B; Prahl A
    Amino Acids; 2012 Aug; 43(2):617-27. PubMed ID: 22038179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine vasopressin and oxytocin effects in mouse pancreatic beta-cells. Receptors involved in stimulation of insulin release.
    Gao ZY; Henquin JC
    Diabetes; 1993 Jun; 42(6):914-21. PubMed ID: 8388343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.
    Manning M; Cheng LL; Klis WA; Stoev S; Przybylski J; Bankowski K; Sawyer WH; Barberis C; Chan WY
    Adv Exp Med Biol; 1995; 395():559-83. PubMed ID: 8714021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas.
    Yibchok-Anun S; Cheng H; Heine PA; Hsu WH
    Am J Physiol; 1999 Jul; 277(1):E56-62. PubMed ID: 10409128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Arg8]vasotocin excites neurones in the dorsal vagal complex in vitro: evidence for an action through novel class(es) of CNS receptors.
    Ingram CD; Tolchard S
    J Neuroendocrinol; 1994 Aug; 6(4):415-22. PubMed ID: 7987372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family.
    Chini B; Mouillac B; Ala Y; Balestre MN; Cotte N; Trumpp-Kallmeyer S; Hoflack J; Elands J; Hibert M; Manning M
    Adv Exp Med Biol; 1995; 395():321-8. PubMed ID: 8713982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of oxytocin receptors, but not arginine-vasopressin V1a receptors, in the ventral tegmental area of male Syrian hamsters is essential for the reward-like properties of social interactions.
    Song Z; Borland JM; Larkin TE; O'Malley M; Albers HE
    Psychoneuroendocrinology; 2016 Dec; 74():164-172. PubMed ID: 27632574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea.
    Akerlund M; Melin P; Maggi M
    Adv Exp Med Biol; 1995; 395():595-600. PubMed ID: 8714023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.